PT Siloam International Hospitals Tbk (SILO) Fair Value & Analysis
Healthcare · ID · Market cap 28.1T IDR
Fair value as of: Jul 12, 2026
From 24 valuation models · updated 28 days ago
Share price +7.7% over the past month.
A solid business, but screening 21% overvalued on our models.
What matters now
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (1,174 IDR to 2,356 IDR) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 545.16 IDR – 3,750 IDR · fair‑value band 1,174 IDR – 2,356 IDR · the 2,380 IDR price screens above the 1,885 IDR fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
PT Siloam International Hospitals Tbk (SILO) currently trades at 2,380 IDR, while our model-based Fair Value estimate is 1,885 IDR, implying the stock looks roughly 20.8% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Siloam International Hospitals Tbk generated revenue of 13.1T IDR at a net margin of 8.8%. Revenue grew 7.9% year over year. It earns a return on equity of 12.5%. Net debt stands at 477B IDR. Fundamentals as of Jul 12, 2026
Our scenario range runs from 1,174 IDR (bear case) to 2,356 IDR (bull case); at 2,380 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 30% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -21%, SILO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (2,083 IDR) versus Asset-Based (500.19 IDR). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services.
Full company description
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it offers services in the areas of andrology, anesthesiology, and arrythmia; cardiothoracic, digestive, general, neuro, pediatric, plastic, and vascular surgery; cardiology, cardiovascular emergency and intensive care, cardiovascular imaging, pediatric cardiology and congenital heart diseases, and preventive cardiology and cardiac rehabilitation; clinical nutrition and psychology; medical acupuncture and laboratory; dermatology, venereology, and aesthetics; and echocardiography, internal medicine, interventional cardiology, neurology, nuclear medicine, obstetrics and gynecologist, occupational medicine, ophthalmology, orthopedic and traumatology, otorhinolaryngology, physical medicine and rehabilitation, pulmonology, radiation oncology, radiology, sports medicine, and urology. Further, it engages in trading, development, mining, agriculture, land transportation, printing, plantation, forestry, electrical, mechanical, engineering, construction, and real estate businesses; computer programming; software publishing and retail trading; provision of management consulting, retail, professional, and scientific and technical; web portal and/or digital platform business; workshops; leasing; wholesale trade; IT; and social services. The company was formerly known as PT Sentralindo Wirasta. PT Siloam International Hospitals Tbk was founded in 1996 and is headquartered in Tangerang, Indonesia. PT Siloam International Hospitals Tbk operates as a subsidiary of Sight Investment Company Pte. Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Siloam International Hospitals Tbk reported revenue of 12.8T IDR in FY2025 versus 9.4T IDR in FY2021, a compound +8.2%/yr. Reported net income was 1.1T IDR in FY2025, compounding +13.3%/yr from FY2021.
SILO screens 21% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Siloam International Hospitals Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Siloam International Hospitals Tbk (SILO) overvalued or undervalued?
What is the fair value of SILO?
What is the quality score of SILO?
What is the revenue of PT Siloam International Hospitals Tbk (SILO)?
What is the net profit margin of SILO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Siloam International Hospitals Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.